Genetic & Genomic MedicineArthritis & RheumatologyPeer-reviewed
Lowering of circulating sclerostin may increase risk of atherosclerosis and its risk factors: evidence from a genome-wide association meta-analysis followed by Mendelian randomization
Jie Zheng, Eleanor Wheeler, Maik Pietzner…·Jonathan H. Tobias
This study uses GWAS and Mendelian randomization to show that lower sclerostin levels increase risk of hypertension, type 2 diabetes, myocardial infarction, and atherogenic lipid profiles.
44 citations